new fda regulations for semaglutide FDA's Removal of and the Evolving Tirzepatide Decisions: What Compounders Need to Know Safe use of compounded GLP

A review of potential options for therapeutic intervention

Price et al., Cell Metabolism )

FDA is requesting that drug application holders remove information regarding the risk of suicidal ideation and behavior (SI/B) from the labeling of glucagon-like peptide-1 receptor agonist (GLP-1 RA) medications that currently include such language

the methods include administering a therapeutically effective amount of the one or more compounds and/or compositions described herein for treating patients with cancer, inflammation, and the like

If were eating a lot of greasy food and were nauseous already on these GLP-1 agonists, thats not going to do us any favors, Cahoon said

There are many different types, each with their own advantages and drawbacks